These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35242380)

  • 1. The co-mutation of
    Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
    J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape and prognosis of patients with
    Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
    Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of tumor mutation burden in
    Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS
    J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational status of main driver genes influences the prognosis of stage I-III lung adenocarcinoma patients underwent radical surgery.
    Liao H; Luo X; Liang Y; Wan R; Xu M
    Transl Cancer Res; 2021 Jul; 10(7):3286-3298. PubMed ID: 35116635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
    Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
    Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
    Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
    Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
    Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
    Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
    Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
    PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
    Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.
    Bai B; An X; Qu Q; Liu X; Liu Y; Wei L
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38872053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel.
    Zhao J; Wu Y; Chen MJ; Xu Y; Zhong W; Wang MZ
    J Thorac Dis; 2022 Dec; 14(12):4669-4684. PubMed ID: 36647494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.